title: [Adalimumab for early rheumatoid arthritis - Chances and risks: Initial analyses of the OPTIMA study].
authors.affiliation: Medizinische Klinik und Poliklinik II, Schwerpunkt Rheumatologie/Immunologie, Universitätsklinikum Würzburg, 97080, Würzburg, Deutschland. schmalzing_m@medizin.uni-wuerzburg.de
authors.forename: M
authors.initials: M
authors.lastname: Schmalzing
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D018501:Antirheumatic Agents / Q000008:administration & dosage*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage*; D020127:Recovery of Function / Q000187:drug effects*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D008727:Methotrexate